A Phase I Open-Label, Non-Randomized, Dose-Escalation Study of rSIFN-co in Subjects With Advanced Solid Tumors and With an Expansion Cohort at Recommended Dose (RD) in Subjects With Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma, Melanoma, Hepatocellular Carcinoma or Colon Cancer

Trial Profile

A Phase I Open-Label, Non-Randomized, Dose-Escalation Study of rSIFN-co in Subjects With Advanced Solid Tumors and With an Expansion Cohort at Recommended Dose (RD) in Subjects With Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma, Melanoma, Hepatocellular Carcinoma or Colon Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs RSIFN-co (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sichuan Huiyang Life Science and Technology Corporation
  • Most Recent Events

    • 10 Dec 2015 According to ClinicalTrials.gov record, the primary end point has been amended.
    • 10 Dec 2015 Planned number of patients changed from 36 to 42, according to ClinicalTrials.gov record.
    • 10 Dec 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top